Literature DB >> 2916237

Differential induction and regulation of peroxisomal enzymes: predictive value of peroxisome proliferation in identifying certain nonmutagenic carcinogens.

M R Nemali1, M K Reddy, N Usuda, P G Reddy, L D Comeau, M S Rao, J K Reddy.   

Abstract

Hypolipidemic drugs and certain plasticizers markedly increase the number of peroxisomes in liver parenchymal cells. Continued exposure to peroxisome proliferators has been shown to produce essentially similar pleiotropic responses leading eventually to the development of liver tumors in rats and mice. These agents are not mutagenic in short-term test systems and do not appear to interact with or damage DNA. Accordingly, the events leading to or associated with the induction of peroxisome proliferation have been postulated to play a role in the development of liver tumors. Recent evidence indicates that persistent peroxisome proliferation leads to the formation of 8-hydroxyguanosine in rat liver DNA, which supports the role for oxidative stress. The mRNAs of the three peroxisomal beta-oxidation genes are induced over 20-fold in the livers of rats treated with nafenopin, Wy-14643, BR-931, and other structurally diverse peroxisome proliferators. This increase in beta-oxidation mRNAs is evident within 30 min to 1 hr and was maximal 8 to 16 hr after the administration of a single dose of these agents by gavage. The peroxisomal catalase and urate oxidase mRNAs increase about 2-fold in the livers of rats treated chronically with peroxisome proliferators. These results indicate that peroxisome proliferators differentially regulate different peroxisomal enzymes. The tissue specificity of peroxisomal beta-oxidation gene regulation by xenobiotics supports the contention that the development of liver tumors following exposure to peroxisome proliferators correlates well with the inducibility of peroxisome proliferation and the beta-oxidation genes. Although these agents are known to exert mitogenic response in liver, it is unlikely that stimulation of DNA synthesis alone is responsible for tumor development. Cell proliferation may, however, play a secondary role. The morphological phenomenon of peroxisome proliferation should serve as a simple, sensitive, and valuable biological indicator for the identification of nongenotoxic or nonmutagenic chemicals that may be carcinogenic. An understanding of the cellular and molecular basis of peroxisome proliferation is a prerequisite for the evaluation of toxicological implications of this phenomenon.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2916237     DOI: 10.1016/0041-008x(89)90056-2

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  8 in total

1.  Sustained formation of alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone radical adducts in mouse liver by peroxisome proliferators is dependent upon peroxisome proliferator-activated receptor-alpha, but not NADPH oxidase.

Authors:  Courtney G Woods; Amanda M Burns; Akira Maki; Blair U Bradford; Michael L Cunningham; Henry D Connor; Maria B Kadiiska; Ronald P Mason; Jeffrey M Peters; Ivan Rusyn
Journal:  Free Radic Biol Med       Date:  2006-11-03       Impact factor: 7.376

2.  Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: comparison of the effects on morphological and biochemical parameters in liver and blood.

Authors:  Amelie Lupp; Elke Karge; Manfred Danz; Thomas Deufel; Herbert Oelschläger; Wolfgang Klinger
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

3.  A negative regulating element controlling transcription of the gene encoding acyl-CoA oxidase in Saccharomyces cerevisiae.

Authors:  T W Wang; A S Lewin; G M Small
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

Review 4.  Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?

Authors:  Jeffrey M Peters; Connie Cheung; Frank J Gonzalez
Journal:  J Mol Med (Berl)       Date:  2005-06-23       Impact factor: 4.599

5.  A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans.

Authors:  Katsutoshi Yoshizato; Chise Tateno
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

6.  Effects of the PPARα Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism.

Authors:  Michael L Cunningham; Bradley J Collins; Milton R Hejtmancik; Ronald A Herbert; Gregory S Travlos; Molly K Vallant; Matthew D Stout
Journal:  PPAR Res       Date:  2010-10-04       Impact factor: 4.964

7.  Clofibrate treatment in pigs: effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents.

Authors:  Sebastian Luci; Beatrice Giemsa; Gerd Hause; Holger Kluge; Klaus Eder
Journal:  BMC Pharmacol       Date:  2007-04-16

8.  HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study.

Authors:  Pavel Dundr; Michaela Bártů; Jan Hojný; Romana Michálková; Nikola Hájková; Ivana Stružinská; Eva Krkavcová; Ladislav Hadravský; Lenka Kleissnerová; Jana Kopejsková; Bui Quang Hiep; Kristýna Němejcová; Radek Jakša; Otakar Čapoun; Jakub Řezáč; Kateřina Jirsová; Věra Franková
Journal:  Sci Rep       Date:  2020-09-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.